An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B
PHASE4CompletedINTERVENTIONAL
Enrollment
59
Participants
Timeline
Start Date
January 31, 2006
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
Conditions
Hepatitis B, Chronic
Interventions
DRUG
Peginterferon alfa-2a [Pegasys]
180 mcg subcutaneously weekly, 48 weeks
Trial Locations (4)
504
Rabat
20100
Casablanca
62000
Rabat
Unknown
Casablanca
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT01787279 - An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B | Biotech Hunter | Biotech Hunter